Evidence map›Paper›PMID 41504388›Full record

ArticleJournal of industrial microbiology & biotechnology2026

Statistical approach for media optimization of fHbp-PorA chimeric protein expression in Escherichia coli; development of a promising Meningococcal B vaccine.

Annamraju Aswini, Annamraju D Sarma, Sambhaji S Pisal, Selvan Ravindran

Abstract read
In one paragraph

Article in Journal of industrial microbiology & biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Annamraju AswiniSerum Institute of India Pvt. Ltd., Hadapsar, Pune, Maharashtra, 411028, India.ORCID 0009-0007-7098-8375
Annamraju D SarmaSerum Institute of India Pvt. Ltd., Hadapsar, Pune, Maharashtra, 411028, India.
Sambhaji S PisalSerum Institute of India Pvt. Ltd., Hadapsar, Pune, Maharashtra, 411028, India.
Selvan RavindranFaculty of Medical and Health Sciences, Symbiosis School of Biological Sciences, Symbiosis International (Deemed University), Lavale, Pune, Maharashtra, 412115, India.ORCID 0000-0001-6846-319X

Funding

Serum Institute of India Pvt. Ltd
6 · The paper itself

Abstract

Successful design of an industrial biological product such as a vaccine requires an efficient, robust and reproducible process. In this study, we investigated conditions for process optimization of a promising recombinant factor H binding protein (fHbp)-Porin A (PorA) chimeric protein-based vaccine candidate against Meningococcal B serogroup in Escherichia coli B834 strain using the inducible T7-lac promoter system. Random screening of components of complex culture media for growth and expression using IPTG as an inducer, showed inconsistency when analyzed using Plackett-Burman design (PBD). Further analysis identified galactose present either in tryptone (as lactose) or soy-phytone, has caused strong autoinduction and is surmised as an interfering factor for IPTG induction. Synergistic combination of soy-phytone and yeast extract under conditions of controlled growth and auto-induction gave a good correlation between the cell growth and expression of the fHbp-PorA chimeric protein when evaluated using PBD and central composite design. Using response optimization conditions, an optimized media was attained. A shake flask study was performed to validate the optimized media, and later, a fed-batch fermentation at 10 L scale was established to prove the scalability, consistency, and product quality using the optimized media. One-sentence summary This study reports optimization of cell growth and expression conditions for a recombinant chimeric meningococcal protein in E. coli that assures its industrial scale production and suitability for preclinical and clinical studies as a vaccine component against Meningococcal B serogroup.

Indexed as

Antigens, BacterialBacterial ProteinsCulture MediaEscherichia coliMeningococcal VaccinesRecombinant Fusion ProteinsFermentationGene ExpressionNeisseria meningitidis, Serogroup BAntigens, BacterialBacterial ProteinsCulture Mediafactor H-binding protein, Neisseria meningitidisMeningococcal VaccinesRecombinant Fusion Proteinsautoinductioncentral composite designEscherichia colifermentationgalactoseMeningococcal B chimeric proteinPlackett–Burman design

Identifiers

PMID41504388
PMCPMC12883990

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.